SARS-CoV-2 escape in vitro from a highly neutralizing COVID-19 convalescent plasma

Cited by (251)

Items 101–200 of 251

1. A molecular sensor determines the ubiquitin substrate specificity of SARS-CoV-2 papain-like protease
   Stephanie Patchett, Zongyang Lv, Wioletta Rut, Miklós Békés, Marcin Drąg, Shaun K. Olsen, Tony T. Huang · 2021 · Cell Reports
2. Tackling COVID-19 with neutralizing monoclonal antibodies
   Davide Corti, Lisa A. Purcell, Gyorgy Snell, David Veesler · 2021 · Cell
3. Nano-Enabled COVID-19 Vaccines: Meeting the Challenges of Durable Antibody Plus Cellular Immunity and Immune Escape
   André E. Nel, Jeff F. Miller · 2021 · ACS Nano
4. Mutational escape from the polyclonal antibody response to SARS-CoV-2 infection is largely shaped by a single class of antibodies
   Allison J. Greaney, Tyler N. Starr, C. Barnes et al. · 2021 · bioRxiv
5. COVID-19 pandemic: SARS-CoV-2 specific vaccines and challenges, protection via BCG trained immunity, and clinical trials
   Wenping Gong, Ashok Aspatwar, Shuyong Wang, Seppo Parkkila, Xueqiong Wu · 2021 · Expert Review of Vaccines
6. Comparative Perturbation-Based Modeling of the SARS-CoV-2 Spike Protein Binding with Host Receptor and Neutralizing Antibodies: Structurally Adaptable Allosteric Communication Hotspots Define Spike Sites Targeted by Global Circulating Mutations
   Gennady M. Verkhivker, Steve Agajanian, Deniz Yaşar Öztaş, Grace Gupta · 2021 · Biochemistry
7. Mortality Benefit of Convalescent Plasma in COVID-19: A Systematic Review and Meta-Analysis
   Vikas Bansal, Kiran Sunil Mahapure, Ishita Mehra, Abhishek Bhurwal, Aysun Tekin, Romil Singh, Ishita Gupta, Sawai Singh Rathore, Hira Khan, Sohiel Deshpande et al. · 2021 · Frontiers in Medicine
8. Immune Escape Associated with RBD Omicron Mutations and SARS-CoV-2 Evolution Dynamics
   Aleksandr V. Kudriavtsev, Anna Vakhrusheva, Valery Nikolaevich Novoseletsky, Marine E. Bozdaganyan, К. В. Шайтан, Mikhail P. Kirpichnikov, Olga S. Sokolova · 2022 · Viruses
9. Immunity to SARS-CoV-2: Lessons Learned
   JAIME E. FERGIE, Amit K. Srivastava · 2021 · Frontiers in Immunology
10. The Development of SARS-CoV-2 Variants: The Gene Makes the Disease
    Raquel Pérez-Gómez · 2021 · Journal of Developmental Biology
11. Dynamic Profiling of Binding and Allosteric Propensities of the SARS-CoV-2 Spike Protein with Different Classes of Antibodies: Mutational and Perturbation-Based Scanning Reveal Allosteric Duality of Functionally Adaptable Hotspots
    Gennady M Verkhivker, Steve Agajanian, D. Oztas · 2021 · bioRxiv
12. Multiple expansions of globally uncommon SARS-CoV-2 lineages in Nigeria
    Egon Anderson Ozer, Lacy M. Simons, Moses Olubusuyi Adewumi, Adeola Fowotade, Ewean Chukwuma Omoruyi, Johnson Adekunle Adeniji, Oluseyi Adebowale Olayinka, Taylor J. Dean, Janet P. Zayas, Pavan P. Bhimalli et al. · 2022 · Nature Communications
13. A review: Antibody-dependent enhancement in COVID-19: The not so friendly side of antibodies
    Gabriela Athziri Sánchez‐Zuno, Mónica Guadalupe Matuz-Flores, Guillermo González-Estévez, Ferdinando Nicoletti, Francisco Javier Turrubiates‐Hernández, Katia Mangano, José Francisco Muñóz-Valle · 2021 · International Journal of Immunopathology and Pharmacology
14. COVID-19, the first pandemic in the post-genomic era
    Lucy van Dorp, Charlotte J. Houldcroft, Damien Richard, François Balloux · 2021 · Current Opinion in Virology
15. Immunogenicity and Protective Efficacy of a Highly Thermotolerant, Trimeric SARS-CoV-2 Receptor Binding Domain Derivative
    S. K. Malladi, U. Patel, Raju S. Rajmani et al. · 2021 · bioRxiv
16. Coincident rapid expansion of two SARS-CoV-2 lineages with enhanced infectivity in Nigeria
    Ozer, Egon A., Simons, Lacy M., Adewumi, Olubusuyi M., Fowotade, Adeola A., Omoruyi, Ewean C., Adeniji, Johnson A., Dean, Taylor J., Zayas, Janet, Bhimalli, Pavan P., Ash, Michelle K. et al. · 2021
17. SARS-CoV-2 Spike Protein Mutations and Escape from Antibodies: A Computational Model of Epitope Loss in Variants of Concern
    Alice Triveri, Stefano Artin Serapian, Filippo Marchetti, Filippo Doria, Silvia Pavoni, Fabrizio Cinquini, Elisabetta Moroni, Andrea Rasola, Francesco Frigerio, Giorgio Colombo · 2021 · Journal of Chemical Information and Modeling
18. 50 Years of structural immunology
    Ian A. Wilson, Robyn L. Stanfield · 2021 · Journal of Biological Chemistry
19. Comparative Perturbation-Based Modeling of the SARS-CoV-2 Spike Protein Binding with Host Receptor and Neutralizing Antibodies : Structurally Adaptable Allosteric Communication Hotspots Define Spike Sites Targeted by Global Circulating Mutations
    Gennady M Verkhivker, Steve Agajanian, D. Oztas · 2021 · bioRxiv
20. A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases
    Jie Zhou, Wei Xu, Zezhong Liu, Chao Wang, Shuai Xia, Qiaoshuai Lan, Yanxing Cai, Shan Su, Jing Pu, Lixiao Xing et al. · 2021 · Acta Pharmaceutica Sinica B
21. Prediction and Evolution of the Molecular Fitness of SARS-CoV-2 Variants: Introducing SpikePro
    Fabrizio Pucci, Marianne J. Rooman · 2021 · Viruses
22. A monoclonal antibody against staphylococcal enterotoxin B superantigen inhibits SARS-CoV-2 entry in vitro
    Mary Hongying Cheng, Rebecca A. Porritt, Magali Noval Rivas, James Krieger, Asli Beyza Ozdemir, Gustavo Garcia, Vaithilingaraja Arumugaswami, Bettina C. Fries, Moshe Arditi, İvet Bahar · 2021 · Structure
23. Molecular characterisation and tracking of severe acute respiratory syndrome coronavirus 2 in Thailand, 2020–2022
    Jiratchaya Puenpa, Patthaya Rattanakomol, Nutsada Saengdao, Jira Chansaenroj, Ritthideach Yorsaeng, Kamol Suwannakarn, Somchai Thanasitthichai, Sompong Vongpunsawad, Yong Poovorawan · 2023 · Archives of Virology
24. Anti-viral treatment for SARS-CoV-2 infection: A race against time amidst the ongoing pandemic
    Natalia G. Vallianou, Dimitrios Tsilingiris, Gerasimos Socrates Christodoulatos, Ιrene Karampela, Μaria Dalamaga · 2021 · Metabolism Open
25. Development of colorimetric sensors based on gold nanoparticles for SARS-CoV-2 RdRp, E and S genes detection
    Ciro Rodríguez-Díaz, Nuria Lafuente‐Gómez, Catarina Coutinho, Demián Pardo, Hernán Alarcón Iniesta, María López‐Valls, Rocío Coloma, Paula Milán-Rois, Mirian Domenech, Melanie Abreu et al. · 2022 · Talanta
26. Allosteric Cross-Talk among Spike’s Receptor-Binding Domain Mutations of the SARS-CoV-2 South African Variant Triggers an Effective Hijacking of Human Cell Receptor
    Angelo Spinello, Andrea Saltalamacchia, Jure Borišek, Alessandra Magistrato · 2021 · The Journal of Physical Chemistry Letters
27. Should we discount the laboratory origin of COVID-19?
    Rossana Segreto, Yuri Deigin, Kevin McCairn, Alejandro Sousa, Dan Sirotkin, Karl M. Sirotkin, Jonathan J. Couey, Adrian Jones, Daoyu Zhang · 2021 · Environmental Chemistry Letters
28. Vaccination with S pan , an antigen guided by SARS-CoV-2 S protein evolution, protects against challenge with viral variants in mice
    Yongliang Zhao, Wenjia Ni, Simeng Liang, Lianghui Dong, Min Xiang, Zeng Cai, Danping Niu, Qiuhan Zhang, Dehe Wang, Yucheng Zheng et al. · 2023 · Science Translational Medicine
29. Role of the Microbiome in the Pathogenesis of COVID-19
    Rituparna De, Shanta Dutta · 2022 · Frontiers in Cellular and Infection Microbiology
30. Impact of the B.1.1.7 variant on neutralizing monoclonal antibodies recognizing diverse epitopes on SARS-CoV-2 Spike
    Graham, Carl, Seow, Jeffrey, Huettner, Isabella, Khan, Hataf, Kouphou, Neophytos, Acors, Sam, Winstone, Helena, Pickering, Suzanne, Galao, Rui Pedro, Lista, Maria Jose et al. · 2021
31. Evolution of the SARS-CoV-2 genome and emergence of variants of concern
    Iman Safari, Elahe Elahi · 2021 · Archives of Virology
32. Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques
    Wanting He, Meng Yuan, Sean Callaghan, Rami Ghassan Musharrafieh, Ge Song, Murillo Silva, Nathan Beutler, Wen-Hsin Lee, Peter Yong, Jonathan L. Torres et al. · 2022 · Science Translational Medicine
33. Structural and Dynamical Differences in the Spike Protein RBD in the SARS-CoV-2 Variants B.1.1.7 and B.1.351
    Nisha Bhattarai, Prabin Baral, Bernard S. Gerstman, Prem P. Chapagain · 2021 · The Journal of Physical Chemistry B
34. Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of Nsp5 main protease
    Jennifer C. Milligan, Theresa U. Zeisner, George Papageorgiou, Dhira Joshi, Christelle Soudy, Rachel Ulferts, Mary Wu, Chew Theng Lim, Kang Wei Tan, Florian Weissmann et al. · 2021 · Biochemical Journal
35. BNT162b2 mRNA COVID‐19 vaccine induces antibodies of broader cross‐reactivity than natural infection, but recognition of mutant viruses is up to 10‐fold reduced
    Xinyue Chang, Gilles Sousa Augusto, Xuelan Liu, Thomas M. Kündig, Monique Vogel, Mona Omar Mohsen, Martin F. Bachmann · 2021 · Allergy
36. Improving family access to dying patients during the COVID-19 pandemic
    James Downar, Mike Kekewich · 2021 · The Lancet Respiratory Medicine
37. Implementing Personalized Medicine in COVID-19 in Andalusia: An Opportunity to Transform the Healthcare System
    Joaquı́n Dopazo, Douglas Maya‐Miles, Féderico García, Nicola Lorusso, Miguel Ángel Calleja, María Jesús Pareja, José López‐Miranda, Jesús Rodríguez‐Baño, Javier Padillo, Isaac Túnez et al. · 2021 · Journal of Personalized Medicine
38. Potential use of convalescent plasma for SARS-CoV-2 prophylaxis and treatment in immunocompromised and vulnerable populations
    Daniele Focosi, Massimo Franchini · 2021 · Expert Review of Vaccines
39. Combination of Angiotensin (1-7) Agonists and Convalescent Plasma as a New Strategy to Overcome Angiotensin Converting Enzyme 2 (ACE2) Inhibition for the Treatment of COVID-19
    Hawraa Issa, Ali Hussein Eid, Bassam Berry, Vahideh Takhviji, Abbas Khosravi, Sarah Mantash, Rawan Nehme, Rawan Hallal, Hussein Karaki, Kawthar Dhayni et al. · 2021 · Frontiers in Medicine
40. Molecular definition of severe acute respiratory syndrome coronavirus 2 receptor‐binding domain mutations: Receptor affinity versus neutralization of receptor interaction
    Monique Vogel, Gilles Sousa Augusto, Xinyue Chang, Xuelan Liu, Daniel E. Speiser, Mona Omar Mohsen, Martin F. Bachmann · 2021 · Allergy
41. A Possible Role of Remdesivir and Plasma Therapy in the Selective Sweep and Emergence of New SARS-CoV-2 Variants
    Philippe Colson, Christian Albert Devaux, Jean‐Christophe Lagier, Philippe Gautret, Didier Raoult · 2021 · Journal of Clinical Medicine
42. Comprehensive Deep Mutational Scanning Reveals the Immune-Escaping Hotspots of SARS-CoV-2 Receptor-Binding Domain Targeting Neutralizing Antibodies
    Keng‐Chang Tsai, Yu-Ching Lee, Tien-Sheng Tseng · 2021 · Frontiers in Microbiology
43. Recent progress on the mutations of SARS-CoV-2 spike protein and suggestions for prevention and controlling of the pandemic
    Xue Li, Liying Zhang, Si Emma Chen, Weilong Ji, Chang Li, Linzhu Ren · 2021 · Infection Genetics and Evolution
44. CONVALESCENT plasma for COVID‐19: A meta‐analysis of clinical trials and real‐world evidence
    Chiraphat Kloypan, Matthanaporn Saesong, Juthamat Sangsuemoon, Prawat Chantharit, Pajaree Mongkhon · 2021 · European Journal of Clinical Investigation
45. Neutralizing Monoclonal Anti-SARS-CoV-2 Antibodies Isolated from Immunized Rabbits Define Novel Vulnerable Spike-Protein Epitope
    Efi Makdasi, Yinon Levy, Ron Alcalay, Tal Noy-Porat, Eran Zahavy, Adva Mechaly, Eyal Epstein, Eldar Peretz, Hila Cohen, Liat Bar‐On et al. · 2021 · Viruses
46. Mechanism of a COVID-19 nanoparticle vaccine candidate that elicits a broadly neutralizing antibody response to SARS-CoV-2 variants
    Yi-Nan Zhang, Jennifer Paynter, Cindy Sou, Tatiana Fourfouris, Ying Wang, Ciril Abraham, Timothy Ngo, Yi Zhang, Linling He, Jiang Zhu · 2021 · Science Advances
47. Anti-SARS-CoV-2 Strategies and the Potential Role of miRNA in the Assessment of COVID-19 Morbidity, Recurrence, and Therapy
    Maria Narożna, Błażej Rubiś · 2021 · International Journal of Molecular Sciences
48. A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection
    Hejun Liu, M. Yuan, De-Li Huang, S. Bangaru, C. D. Lee, Linghang Peng, Xue-Yong Zhu, D. Nemazee, M. V. van Gils, R. Sanders et al. · 2021 · bioRxiv
49. Nasal delivery of broadly neutralizing antibodies protects mice from lethal challenge with SARS-CoV-2 delta and omicron variants
    Jia Lu, Qiangling Yin, Rongjuan Pei, Qiu Zhang, Yuanyuan Qu, Yongbing Pan, Lina Sun, Ding Gao, Cuiqin Liang, Jingwen Yang et al. · 2022 · Virologica Sinica
50. Anti-SARS-CoV-1 and −2 nanobody engineering towards avidity-inspired therapeutics
    Eugene Marfo Obeng, Christian K. O. Dzuvor, Michael K. Danquah · 2021 · Nano Today
51. SARS-CoV-2 vaccines: A critical perspective through efficacy data and barriers to herd immunity
    Francesco Blasi, Andrea Gramegna, Giovanni Sotgiu, Laura Saderi, Antonio Voza, Stefano Aliberti, Francesco Amati · 2021 · Respiratory Medicine
52. SARS-CoV-2 Main Protease Active Site Ligands in the Human Metabolome
    Anna Maria Sardanelli, Camilla Isgrò, Luigi Leonardo Palese · 2021 · Molecules
53. High Individual Heterogeneity of Neutralizing Activities against the Original Strain and Nine Different Variants of SARS-CoV-2
    Rita Jaafar, Céline Boschi, Sarah Aherfi, Audrey Bancod, Marion Le Bideau, Sophie Edouard, Philippe Colson, Henri Chahinian, Didier Raoult, Nouara Yahi et al. · 2021 · Viruses
54. Prefusion spike protein conformational changes are slower in SARS-CoV-2 than in SARS-CoV-1
    Vivek Govind Kumar, Dylan S. Ogden, Ugochi H. Isu, Adithya Polasa, James Losey, Mahmoud Moradi · 2022 · Journal of Biological Chemistry
55. Determination of the Concentration of IgG against the Spike Receptor-Binding Domain That Predicts the Viral Neutralizing Activity of Convalescent Plasma and Serum against SARS-CoV-2
    Llipsy Santiago, Iratxe Uranga-Murillo, Maykel A. Arias, Andrés Manuel González‐Ramírez, Javier Macías‐León, Eduardo Moreo, Sergio Redrado, Ana García‐García, Víctor Taleb, Erandi Lira‐Navarrete et al. · 2021 · Biology
56. A phylogeny-based metric for estimating changes in transmissibility from recurrent mutations in SARS-CoV-2
    Damien Richard, Liam P. Shaw, Robert Lanfear, Russell B Corbett-Detig, Angie S. Hinrichs, Jakob McBroome, Yatish Turakhia, Mislav Acman, Christopher J. Owen, Cedric C.S. Tan et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
57. COVID‐19: emergence and mutational diversification of SARS‐CoV‐2
    Harald Brüssow · 2021 · Microbial Biotechnology
58. COVID-19 Infection Among Women in Iran Exposed vs Unexposed to Children Who Received Attenuated Poliovirus Used in Oral Polio Vaccine
    F. Habibzadeh, Mohammad M. Sajadi, Konstantin Chumakov, M. Yadollahie, Shyamasundaran Kottilil, A. Simi, K. Stafford, Saeid Saeidimehr, M. Rafiei, Robert C. Gallo · 2021 · JAMA Network Open
59. Molecular variants of SARS-CoV-2: antigenic properties and current vaccine efficacy
    Amirmasoud Rayati Damavandi, Razieh Dowran, Sarah Al Sharif, Fatah Kashanchi, Reza Jafari · 2022 · Medical Microbiology and Immunology
60. Broad ultra-potent neutralization of SARS-CoV-2 variants by monoclonal antibodies specific to the tip of RBD
    Hang Ma, Yingying Guo, Haoneng Tang, Chien-Te Kent Tseng, Lei Wang, Huifang Zong, Zhenyu Wang, Yang He, Yunsong Chang, Shusheng Wang et al. · 2022 · Cell Discovery
61. Possible Targets of Pan-Coronavirus Antiviral Strategies for Emerging or Re-Emerging Coronaviruses
    Xue Li, Liying Zhang, Si Emma Chen, Hongsheng Ouyang, Linzhu Ren · 2021 · Microorganisms
62. Regulatory concepts to guide and promote the accelerated but safe clinical development and licensure of COVID‐19 vaccines in Europe
    Ralf Wagner, Juliane Meißner, Elena Grabski, Yuansheng Sun, Stefan Vieths, Eberhard Hildt · 2021 · Allergy
63. Research progress on vaccine efficacy against SARS-CoV-2 variants of concern
    Lianlian Bian, Jianyang Liu, Fan Gao, Qiushuang Gao, Qian He, Qunying Mao, Xing Wu, Miao Xu, Zhenglun Liang · 2022 · Human Vaccines & Immunotherapeutics
64. Passive Immunity Trial for Our Nation (PassITON): study protocol for a randomized placebo-control clinical trial evaluating COVID-19 convalescent plasma in hospitalized adults
    For the Passive Immunity Trial for Our Nation (PassITON) Investigators, Wesley H. Self, Thomas G. Stewart, Allison P. Wheeler, Wissam El Atrouni, Amanda J. Bistran-Hall, Jonathan Dale Casey, Vince D. Cataldo, James D. Chappell, Claudia S. Cohn et al. · 2021 · Trials
65. Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines
    A. Walls, Marcos C. Miranda, Minh N. Pham, A. Schäfer, Allison J. Greaney, Prabhu S. Arunachalam, M. Navarro, M. A. Tortorici, Kenneth A. Rogers, Megan A. O'Connor et al. · 2021 · bioRxiv
66. Convalescent plasma (hyperimmune immunoglobulin) for COVID-19 management: An update
    Vivek P. Chavda, Rajashri Bezbaruah, Sheetal Dolia, Nirav Shah, Sachin Verma, Shrinivas S. Savale, Suma Ray · 2023 · Process Biochemistry
67. Analysis of SARS-CoV-2 mutations in the main viral protease (NSP5) and its implications on the vaccine designing strategies
    Niti Yashvardhini, Amit Kumar, Deepak Kumar Jha · 2022 · Vacunas (English Edition)
68. Pseudotyped Bat Coronavirus RaTG13 is efficiently neutralised by convalescent sera from SARS-CoV-2 infected patients
    Diego M. Cantoni, Martin Mayora Neto, Nazia Thakur, Ahmed M. E. Elrefaey, Joseph Newman, Sneha Vishwanath, Angalee Nadesalingam, Andrew Chan, Peter Smith, Javier Castillo‐Olivares et al. · 2022 · Communications Biology
69. SARS CoV-2 escape variants exhibit differential infectivity and neutralization sensitivity to convalescent or post-vaccination sera
    A. Kuzmina, Yara Khalaila, O. Voloshin, Ayelet Keren-Naus, Liora Bohehm, Y. Raviv, Y. Shemer-Avni, Elli Rosenberg, R. Taube · 2021 · medRxiv
70. A novel diagnostic test to screen SARS-CoV-2 variants containing E484K and N501Y mutations
    Yanan Zhao, Annie Lee, Kaelea Composto, Marcus H. Cunningham, José R. Mediavilla, Samantha Fennessey, André Corvelo, Kar Fai Chow, Michael C. Zody, Liang Chen et al. · 2021 · Emerging Microbes & Infections
71. Tracking the turnover of SARS-CoV-2 VOCs Gamma to Delta in a Brazilian state (Minas Gerais) with a high-vaccination status
    Paula Luize Camargos Fonseca, Filipe Romero Rebello Moreira, Rafael Marques de Souza, Natália R Guimarães, Nara de Oliveira Carvalho, Talita Adelino, Hugo José Alves, Luige Biciati Alvim, Darlan da Silva Cândido, Helena Perez Coelho et al. · 2022 · Virus Evolution
72. Covalent coupling of Spike’s receptor binding domain to a multimeric carrier produces a high immune response against SARS-CoV-2
    Paula M. Berguer, Matı́as Blaustein, Luis M. Bredeston, Patricio O. Craig, Cecilia D’Alessio, Fernanda Elias, Paola C. Farré, Natalia Fernández, Hernán Gentili, Yamila B. Gándola et al. · 2022 · Scientific Reports
73. B-Cell Memory Responses to Variant Viral Antigens
    Harry N White · 2021 · Viruses
74. Molecular strategies for antibody binding and escape of SARS-CoV-2 and its mutations
    Mohamed A Hendy, Samuel Kaufman, Mauricio Rene Ponga · 2021 · Scientific Reports
75. Licorice-saponin A3 is a broad-spectrum inhibitor for COVID-19 by targeting viral spike and anti-inflammation
    Yi Yang, Wenzhe Li, Kefang Liu, Heng Xue, Rong Yu, Meng Zhang, Yang‐Oujie Bao, Xinyuan Lai, Jingjing Fan, Yuxi Huang et al. · 2023 · Journal of Pharmaceutical Analysis
76. Evaluation of mRNA-1273 against SARS-CoV-2 B.1.351 Infection in Nonhuman Primates
    Kizzmekia S. Corbett, Anne P. Werner, Sarah O’ Connell, Matthew Gagné, Lilin Lai, Juan I. Moliva, Barbara J. Flynn, Angela Choi, Matthew J. Koch, Kathryn E. Foulds et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
77. Mechanism of a COVID-19 nanoparticle vaccine candidate that elicits a broadly neutralizing antibody response to SARS-CoV-2 variants
    Yi-Nan Zhang, J. Paynter, Cindy Sou, Tatiana Fourfouris, Ying Wang, Ciril Abraham, Timothy A Ngo, Yi Zhang, Lin-Ling He, Jiang Zhu · 2021 · bioRxiv
78. Protein Scaffold‐Based Multimerization of Soluble ACE2 Efficiently Blocks SARS‐CoV‐2 Infection In Vitro and In Vivo
    Alişan Kayabölen, Uğur Akcan, Doğancan Özturan, Hivda Ülbeği Polat, Gizem Nur Şahin, Nareg Pinarbasi Degirmenci, Canan Bayraktar, Gizem Söyler, Ehsan Sarayloo, Elif Nurtop et al. · 2022 · Advanced Science
79. SARS-CoV-2: An Overview of the Genetic Profile and Vaccine Effectiveness of the Five Variants of Concern
    Raluca Dumache, Alexandra Enache, Ioana Gabriela Macasoi, Cristina Adriana Dehelean, Victor Cristian Dumitrascu, Alexandra Mihailescu, Roxana Popescu, Mihaela Vlad, Cristian Sebastian Vlad, Camelia Oana Mureşan · 2022 · Pathogens
80. A Potential Role of the CD47/SIRPalpha Axis in COVID-19 Pathogenesis
    Katie-May McLaughlin, Denisa Bojková, Joshua D. Kandler, Marco Bechtel, Philipp Reus, Trang T. Le, Florian Rothweiler, Julian U. G. Wagner, Andreas Weigert, Sandra Ciesek et al. · 2021 · Current Issues in Molecular Biology
81. The neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal antibodies is retained against viral variants
    Efi Makdasi, Anat Zvi, Ron Alcalay, Tal Noy-Porat, Eldar Peretz, Adva Mechaly, Yinon Levy, Eyal Epstein, Theodor Chitlaru, Ariel Tennenhouse et al. · 2021 · Cell Reports
82. Sequence signatures of two IGHV3-53/3-66 public clonotypes to SARS-CoV-2 receptor binding domain
    2021
83. Implications of the Immune Polymorphisms of the Host and the Genetic Variability of SARS-CoV-2 in the Development of COVID-19
    Jesús Zepeda–Cervantes, Daniel Martínez-Flores, Josué O. Ramírez‐Jarquín, Ángeles C. Tecalco-Cruz, Noé Santiago Alavez-Pérez, Luis A. Vaca, Rosa Elena Sarmiento Silva · 2022 · Viruses
84. Protection against SARS-CoV-2 Beta Variant in mRNA-1273 Boosted Nonhuman Primates
    Kizzmekia S. Corbett, Matthew Gagné, Danielle A. Wagner, Sarah O’ Connell, Sandeep Narpala, Dillon R. Flebbe, Shayne F. Andrew, Rachel L. Davis, Barbara J. Flynn, Timothy S. Johnston et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
85. Understanding COVID-19: are children the key?
    Suz Warner, Alex G Richter, Zania Stamataki, Deirdre Anne Kelly · 2021 · BMJ Paediatrics Open
86. Antigen–Antibody Complex-Guided Exploration of the Hotspots Conferring the Immune-Escaping Ability of the SARS-CoV-2 RBD
    Kit-Man Fung, Shu-Jung Lai, Tzu-Lu Lin, Tien‐Sheng Tseng · 2022 · Frontiers in Molecular Biosciences
87. Variantes del SARS-CoV-2: epidemiología, fisiopatología y la importancia de las vacunas
    Marcelo Bedoya-Sommerkamp, Jesús Medina-Ranilla, Victor Hugo Chau Rodriguez, Renato Li-Soldevilla, Álvaro Vera-Albújar, Patricia Jannet Garcia · 2021 · Revista Peruana de Medicina Experimental y Salud Pública
88. Murine Monoclonal Antibodies against the Receptor Binding Domain of SARS-CoV-2 Neutralize Authentic Wild-Type SARS-CoV-2 as Well as B.1.1.7 and B.1.351 Viruses and Protect In Vivo in a Mouse Model in a Neutralization-Dependent Manner
    Fatima Amanat, Shirin Strohmeier, Wen-Hsin Lee, Sandhya Bangaru, Andrew B. Ward, Lynda Coughlan, Florian Krammer · 2021 · mBio
89. Covid-19 convalescent plasma therapy: Analyzing the factors that led to its failure in India
    Naveen Bansal, Manish Raturi, Yashik Bansal · 2021 · Transfusion Clinique et Biologique
90. Altered Local Interactions and Long-Range Communications in UK Variant (B.1.1.7) Spike Glycoprotein
    Stefano Borocci, Carmen Cerchia, Alessandro Grottesi, Nico Sanna, Ingrid G. Prandi, Nabil Abid, Andrea R. Beccari, Giovanni Chillemi, Carmine Talarico · 2021 · International Journal of Molecular Sciences
91. Amino acids 484 and 494 of SARS-CoV-2 spike are hotspots of immune evasion affecting antibody but not ACE2 binding
    Marta Alenquer, Filipe Ferreira, Diana Lousa, Mariana Valério, Mónica Medina-Lopes, Marie‐Louise Bergman, Juliana Gonçalves, Jocelyne Demengeot, Ricardo B. Leite, Jingtao Lilue et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
92. The adaptation of SARS-CoV-2 to humans
    Eduardo Tosta · 2021 · Memórias do Instituto Oswaldo Cruz
93. Murine monoclonal antibodies against RBD of the SARS-CoV-2 spike protein as useful analytical tools for subunit vaccine development and clinical trials
    Omar R. Blanco, Dayamí Dorta, Carlos A. Hernández, Daymí Abreu, Andy G. Domínguez, Yaramis Luna, Onel Valdivia, Maylín Pérez-Bernal, Celia Tamayo, Gilda Lemos et al. · 2021 · Journal of Immunological Methods
94. Human-to-dog Transmission of SARS-CoV-2 Lota Variant: Should COVID-19 Patients Avoid Close Contact with their Pets During Illness?
    Ricardo Rivero, Evelin Garay, Yesica Botero, Hector Serrano-Coll, Bertha Gastelbondo, Marina Muñoz, Nathalia Ballesteros, Sergio Castañeda, Luz Helena Patiño, Juan David Ramirez et al. · 2021 · Research Square
95. Pressing Questions and Challenges in the HIV-1 and SARS-CoV-2 Syndemic
    Monty A Montano · 2021 · AIDS Research and Human Retroviruses
96. SARS-CoV-2 transmission, vaccination rate and the fate of resistant strains
    Simon A. Rella, Y. A. Kulikova, E. Dermitzakis, F. A. Kondrashov · 2021 · medRxiv
97. Potential antiviral effects of pantethine against SARS-CoV-2
    Mhamad Abou-Hamdan, Rachelle Saleh, Shyamala Mani, Pascal Dournaud, Mathieu Métifiot, Marie-Lise Blondot, Marie‐Line Andréola, Fadi Abdel‐Sater, Max L. De Reggi, Pierre Gressèns et al. · 2023 · Scientific Reports
98. Appraisal of SARS-CoV-2 mutations and their impact on vaccination efficacy: an overview
    Nastaran Hadizadeh, Mousa Naderi, Jafar Khezri, Meysam Yazdani, Mehdi Shamsara, Ehsan Hashemi · 2022 · Journal of Diabetes & Metabolic Disorders
99. An Overview of SARS-CoV-2 Molecular Diagnostics in Europe
    Emma Ann Davies, Hamzah Z. Farooq, Benjamin Brown, Peter Tilston, Ashley Kate McEwan, Andrew Birtles, Robert William O'Hara, Shazaad S. Y. Ahmad, Nicholas W. Machin, Louise M Hesketh et al. · 2022 · Clinics in Laboratory Medicine
100. A single intramuscular injection of monoclonal antibody MAD0004J08 induces in healthy adults SARS-CoV-2 neutralising antibody titres exceeding those induced by infection and vaccination
     S. Lanini, S. Milleri, Emanuele Andreano et al. · 2021 · medRxiv